Short-Term Induction Therapy with Anti-Thymocyte Globulin and Delayed Use of Calcineurin Inhibitors in Orthotopic Liver Transplantation

Citations Over TimeTop 10% of 2007 papers

Abstract

The appropriate time point for starting immunosuppressive treatment with calcineurin inhibitors after orthotopic liver transplantation (OLT) has been a subject of debate. The aim of the study was to analyze the effects of anti-thymocyte globulin (ATG) induction therapy on rejection, renal function, infection, tumor rate, and survival. We retrospectively analyzed 391 patients after OLT who had either received calcineurin inhibitors immediately after OLT (n = 129) or after an initial short-term Thymoglobulin induction therapy (n = 262). The 1-year acute rejection rate was 14.5% vs. 31.8% in favor of ATG (P = 0.0008). Rejection grades and the need for treatment also differed significantly (7.3% vs. 23.3%; P = 0.001). Serum creatinine at transplantation was similar in both groups (1.14 mg/dL vs.1.18 mg/dL; P = NS). Postoperative hemofiltration was less frequently seen after induction therapy (P 0.05). Short-term ATG induction therapy with delayed administration of calcineurin inhibitors led to a more favorable rejection rate and an improved clinical course in case of a rejection episode. It has beneficial effects on renal function immediately after OLT as well as later, and no additional harmful effects.

Related Papers

• → Anti-thymocyte globulin dosing—per kg or per lymphocyte?(2017)4 cited
• → Comparison of Efficacy and Safety Between Rabbit Anti-Thymocyte Globulin and Anti-T Lymphocyte Globulin in Kidney Only Transplantation(2022)1 cited
• → Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft-vs.-Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)(2011)
• → 75: Short Term Outcomes Using CD3 Guided Low Dose Anti Thymocyte Globulin To Avoid Early Calcineurin Inhibition after Cardiac Transplantation(2009)
• → Biologics in Transplantation (Anti-thymocyte Globulin, Belatacept, Alemtuzumab): How Should We Use Them?(2017)